Restasis: how international patients access US-sourced specialty supply
Restasis (cyclosporine ophthalmic emulsion 0.05 percent) is coordinated by Reserve Meds for international patients via physician-led, US-sourced, named-patient cross-border supply.
This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions. Reserve Meds does not make insurance or pharmacy-assistance-program promises.
Quick orientation
Restasis (cyclosporine ophthalmic emulsion 0.05 percent) is sponsored by Allergan / AbbVie and received first US FDA approval in 2003. It is delivered as ophthalmic, one drop in each eye twice daily. The US label covers increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (dry eye disease). Mechanistically, Cyclosporine is a calcineurin inhibitor.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
US wholesale acquisition cost (WAC) is the published US specialty-distribution list price and is not the same as a single-payer negotiated price. US WAC for Restasis commonly runs around USD 600 to USD 800 per 30-day single-use vial supply. Patient out-of-pocket via cross-border supply is the US WAC plus logistics, IOR / customs, translation, and a Reserve Meds concierge fee; it is not a route to local-formulary pricing.
Mechanism of action
Cyclosporine is a calcineurin inhibitor. At a topical 0.05 percent emulsion, it modulates T-cell-driven inflammation on the ocular surface and lacrimal gland, helping restore baseline tear production over weeks of consistent use. It is not a tear substitute and does not provide acute relief; the effect is anti-inflammatory and chronic.
Why Restasis routes via cross-border NPP internationally
Restasis is widely registered globally, but generic and biosimilar cyclosporine 0.05 percent supply is uneven across MENA and South Asia, and some local formulations differ on excipient profile. Patients who are stable on US Restasis and traveling or relocating, or who require the originator product on a clinical-justification basis (severe SS-related dry eye, post-corneal-graft), often need named-patient or personal-import import to maintain continuity.
The patterns that produce cross-border demand for Restasis are consistent across destination countries: meaningful registration lag relative to the US label, indication-specific dosing complexity that makes substitution clinically risky, payer denial patterns that exclude newer or expanded indications, and the global specialty distribution model in which the originator manufacturer routes specialty supply through a small number of authorized US wholesalers. Reserve Meds sits inside that authorized supply lane, not outside it.
How Reserve Meds coordinates supply
Every Restasis case follows the same physician-led, document-first workflow:
- The treating physician issues a prescription and clinical justification letter.
- Reserve Meds clinical and regulatory review assesses indication fit and destination-country pathway eligibility.
- Country-specific named-patient or personal-import documentation is prepared, translated where required, and submitted to the destination-country regulator under the local lawful import framework.
- Supply is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability (a federal track-and-trace requirement) and unbroken chain of custody from US warehouse forward.
- Cold-chain handling is validated where applicable; temperature is monitored end-to-end with audit logs.
- Shipment is coordinated to the patient's treating physician or hospital pharmacy, not directly to consumers.
Reserve Meds does not handle controlled substances. We do not promise pharmacy assistance program enrollment, manufacturer copay support, or insurance reimbursement; those are different commercial frameworks aimed at US-domiciled patients.
Common cross-border destinations
Restasis cross-border demand concentrates in markets where US specialty supply is the most reliable path to the labeled indication. We publish destination-country deep-dives where local matrix cells exist; the rest are coordinated case-by-case on the same physician-led workflow.
Across each of these destinations, three structural patterns repeat. First, the local regulator maintains a named-patient or personal-import framework precisely so clinicians can reach a labeled US therapy for individual patients whose case cannot wait for full local registration. Second, that framework is document-driven, which means the work of cross-border access is the work of preparing a defensible clinical and regulatory dossier rather than chasing inventory. Third, the destination-country specialist (the treating physician) signs the case in; Reserve Meds operates on top of that signature, not in place of it.
Real cost picture
Monthly drug-only cost at US WAC is typically USD 600 to USD 800. Restasis single-use vials are stable at room temperature, so logistics cost is modest. Reserve Meds quotes firm pricing post-document review.
A formal Reserve Meds quote breaks out: drug cost at US WAC; cold-chain 3PL handling where applicable; IOR, customs, and destination-country regulatory fees; certified translation of physician documentation; and a tiered Reserve Meds concierge fee layered on the drug cost rather than per-dose. The indicative range above is for orientation; a firm quote is issued after physician documentation is reviewed.
Reserve Meds does not charge intake deposits. Patients pay the firm-quoted amount in full only after accepting the quote, with a defined refund posture for procurement failure or gross negligence as set out in the engagement documentation. Delivery or transit-failure outcomes are handled via insurance and replacement coordination rather than refund, because once a US procurement chain is committed, the drug is committed.
Manufacturer context and global distribution
Restasis is manufactured by Allergan / AbbVie. Like most US specialty therapies, it is routed through a narrow set of authorized specialty wholesalers under DSCSA (Drug Supply Chain Security Act) track-and-trace rules. That is the same supply lane US specialty pharmacies use; cross-border named-patient access works by attaching destination-country regulatory documentation to a shipment that originates inside that authorized lane, not by sourcing outside it. Counterfeit and parallel-trade exposure is concentrated outside that lane, which is precisely why Reserve Meds will not source from secondary or grey-market channels regardless of price.
Serial-number traceability is preserved end-to-end. Every Restasis pack or vial carries the US wholesaler's lot and serial-number documentation forward into the destination-country regulatory submission, which is what allows the destination regulator to verify provenance on inspection.
What your physician provides
For Reserve Meds to coordinate Restasis, the treating physician provides a treating-ophthalmologist prescription, a clinical justification letter documenting dry eye severity and prior tear-substitute / anti-inflammatory therapy history, license verification, and a follow-up plan for ocular-surface monitoring. Reserve Meds does not substitute for treating-physician judgment, does not prescribe, and does not advise on individual patient suitability; that is the treating physician's role.
Common questions
Is Restasis a quick-relief eye drop?
No. It is anti-inflammatory and chronic-use; benefit typically builds over several weeks of consistent twice-daily dosing.
Can Restasis be combined with tear substitutes?
Yes. Tear substitutes and Restasis are typically used together, with a 15-minute gap between drops.
Is Restasis the same as topical Sandimmune?
No. Restasis is a 0.05 percent ophthalmic emulsion specifically developed for ocular surface use; systemic cyclosporine formulations are different products.
Does it require cold chain?
No. Restasis single-use vials are stable at controlled room temperature, which simplifies international shipping.
Is generic cyclosporine 0.05 percent the same as Restasis?
Generics share the active ingredient. Patients stable on the originator sometimes prefer not to switch; that is a clinical judgment for the treating ophthalmologist.
Indicative timing
Time-to-first-dose for Restasis is dominated by destination-country regulatory turnaround on the named-patient or personal-import submission, not by US procurement (which is typically days, not weeks, for an authorized specialty wholesaler with serialized stock). In faster markets (UAE Ministry of Health and Prevention named-patient track, Saudi SFDA named-patient track), the regulatory clock is commonly under 4 weeks when the dossier is complete on first submission. In slower markets or where translations and additional attestations are required, the regulatory clock can extend to 6 to 10 weeks. Reserve Meds frames every Restasis timeline as an indicative range with a defined gating event (regulator acknowledgement), not as a guaranteed delivery date.
Subsequent cycles are materially faster than the first cycle because the regulatory file, physician credentials, and import authorization are already on record. For chronic-use therapies like Restasis, the first cycle carries the regulatory overhead; the rest is logistics.
Where Reserve Meds fits in
Reserve Meds is the named cross-border coordinator. A dedicated patient coordinator owns the case from intake through delivery, the clinical and regulatory teams handle the document chain, and a DSCSA-compliant specialty wholesaler is the source of every vial or pack. We work in service of the treating-physician relationship, not around it.
Patients deal with one named coordinator from intake through delivery. Physicians deal with a clinical-and-regulatory contact who speaks the language of the destination regulator and of US specialty pharmacy. That single-point-of-contact structure is deliberate: cross-border specialty access fails most often at the seams between parties, not inside any single step, and Reserve Meds is built to own the seams.
Next step
Submit a 60-second intake. Our clinical team will respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote.
For broader disease context, see our Dry Eye Disease overview.